Edison Investment Research initiates coverage on Cytori Therapeutics

     Edison Investment Research initiates coverage on Cytori Therapeutics

PR Newswire

LONDON, Feb. 4, 2014

LONDON, Feb. 4, 2014 /PRNewswire/ --Edison's first report on Cytori
Therapeutics, Cardiac Celution, discusses the use of concentrated adipose
(fat) derived regenerative cells (ADRC) from the patient, which, when injected
into damaged tissues, appear to trigger their healing. Cytori sells Celution,
point-of-care disposables and a bedside device to prepare ADRC in 90 minutes
or less. The procedure is flexible to use, with a potentially broad range of
indications and an affordable price point.

We value Cytori at $230m or $3.10/share using a pre-tax 2025 multiple of 15x,
which suggests the company offers a strong investment case in cell therapy.

For the full report see:
www.edisoninvestmentresearch.com/research/company/cytori-therapeutics

All reports published by Edison are available to download free of charge from
its website www.edisongroup.com. 

Key links/tags: Healthcare, equipment, services, cell therapy, regenerative,
cardiology, heart, ADRC

Overview of company: Cytori Therapeutics produces concentrated regenerative
cells from adipose tissue using a bedside device and disposables. The unit is
sold in Japan and the EU. The cells are administered to damaged heart muscle
to improve heart function. There is also a US government (BARDA) contract to
develop regenerative cells for burns therapy and a hamstring repair
indication. Lorem Vascular will sell in China and South-East Asia.

About Edison: Edison, the investment intelligence firm, is the future of
investor interaction with corporates. Our team of over 100 analysts and
investment professionals works with leading companies, fund managers and
investment banks worldwide to support its capital markets activity. We provide
services to more than 400 retained corporate and investor clients from our
offices in London, New York, Frankfurt, Sydney and Wellington. Edison is
authorised and regulated by the Financial Conduct Authority
(www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison
on:

LinkedIn www.linkedin.com/company/edison-investment-research
Twitter  www.twitter.com/Edison_Inv_Res
YouTube  www.youtube.com/edisonitv

SOURCE Edison Investment Research

Website: http://www.edisongroup.com
 
Press spacebar to pause and continue. Press esc to stop.